BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and MedTech

Boston Consulting Group and Hippocratic AI announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of generative AI health care agents. The partnership combines Hippocratic AI’s safety-first technology and health care specialization with BCG’s strategic, operational, and AI transformation expertise to help organizations unlock measurable value across the life sciences value chain.

Despite significant investment in digital technology, BCG benchmarks show that only a small percentage of biopharma and medtech companies are realizing sustained value from AI. This collaboration is designed to close that gap by moving organizations from experimentation to enterprise-scale impact.

A Partnership Built for Impact

Hippocratic AI contributes best-in-class generative AI health care agents, purpose-built for regulated clinical and life sciences environments. With over 150 million clinical interactions to date, these agents support non-diagnostic, patient-facing clinical and operational tasks such as patient onboarding, adherence engagement, clinical trial coordination, and post-market follow-up. Built on Hippocratic AI’s proprietary Polaris Constellation architecture, the agents deliver consistent, safe, empathetic performance that augments human teams.

BCG brings C-suite advisory and AI transformation leadership, including its proprietary Health Care Commercial AI by BCG X offering designed to help health care leaders modernize their commercial models, improve omnichannel engagement, and achieve measurable performance gains. The firm’s insights are supported by ongoing research from BCG X, the tech build and design division of BCG, including benchmark studies and global roundtables focused on AI adoption in biopharma and medtech.

“This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI’s sophisticated AI agent platform, BCG’s strategy and governance expertise, and BCG X’s Health Care Commercial AI solution to help clients turn potential into measurable business value,” said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X.

“Our collaboration with BCG is built on a shared commitment to improving patient outcomes,” said Munjal Shah, Founder and CEO of Hippocratic AI. “By combining BCG’s deep strategic and operational expertise with our safety-focused generative AI health care agents, we can accelerate innovation across biopharma and medtech, bringing scalable, empathetic, and clinically aligned support to patients, providers, and researchers around the world.”

Source: Boston Consulting Group and Hippocratic AI media announcement